At a glance
- Originator Mitsubishi Chemical
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 07 Jun 2001 Discontinued-I for Hyperlipidaemia in Japan (Unknown route)
- 01 Nov 1998 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)
- 01 Aug 1996 Phase-I clinical trials for Hyperlipidaemia in Japan (Unknown route)